| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.15 | 0.001 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.006 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.007 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.092 | 0.008 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.088 | 0.01 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.079 | 0.01 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.02 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.12 | 0.02 |